Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Prednisolone, Rituximab, and Vincristine in patients with Non-Hodgkin Lymphoma.

Statements

Source and description
Rituxan (rituximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (21 days) for reimbursement as a treatment option for the treatemnt of patients with CD20 positive non-Hodgkin's lymphoma. This indication is also generally for cyclophosphamide, doxorubicin, vincristine, and prednisolone as a treatment option for patients non-Hodgkin's lymphoma, and the treatment regimen notes that rituximab should be included for CD20+ patients.
MabThera (rituximab) [product information]. EMA. The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.